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A cohort of patients was extracted from Epic using Webi via 2019 ICD-10-CM 
Diagnoses Code R57.0 (Cardiogenic Shock) that was both primary and 
subsequent. This technique was also used to find the population of STEMI 
patients within this cohort. 
The demographic information for CS patients (n=1534) and the hemodynamic 
lab values, presenting symptoms, and MCSD usage for STEMI patients (n=260) 
was collected and stored using EPIC and REDCap for patients at LVHN-CC, 
including transfers. Patients were then sorted into the fiscal year in which they 
presented to the hospital with their condition.
• NSTEMI patients within the CS population should be analyzed 
for PCI/MCSD usage and their hemodynamic values should be 
recorded to augment hemodynamic data for further 
investigation.
• A crosswalk should be performed to compare patients 
identified as CS via ICD-10-CM diagnoses codes with clinical 
criteria to improve the internal validity of population inclusion.
• Trends in comprehensive hemodynamic measurements 
collected during right heart catheterization procedures for both 
STEMI and NSTEMI shock patients should be analyzed further 
for values that may correlate with mortality rates.
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This retrospective analysis of fiscal years 2016-2019 was conducted 
to visualize the demographic composition of a cardiogenic shock 
patient population (n=1534) in addition to the hemodynamic profile 

































Payor Type by % for CS Population (n=1534)
Prevalence and Mortality for CS and STEMI during FY's 2016-19
FY 19 FY 18 FY 17 FY 16
CS
Prevalence
425                 
273 M vs. 152 F
419                
270 M vs. 149 F
402               
265 M vs. 137 F
287                
180 M vs. 107 F
Mortality
Total: 36.2% Total: 32.9% Total: 32.33% Total: 32.7%
M 99/154 M 78/138 M 78/130 M 61/94
F 55/154 F 60/138 F 52/130 F 33/94
STEMI
Prevalence 18.35% 14.10% 15.17% 21.25%
Mortality
Total: 38.4% Total: 44.1% Total: 32.8% Total: 32.7%
M 18/30 M 18/26 M 11/20 M 11/19
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Below 34 35-44 45-54 55-64 65-74 75-84 85+
Patient Population and Mortality per Age Range during 
FY 2016-19 
Patients in Age Range Mortality
• Throughout FY 2016-2019, 63-66% of the CS population was 
male and there was a 32-36% mortality rate for all patients.
• Patients within the age range of 35-64 had an overall average 
mortality rate of 27.73%.
• MCSD usage has significantly shifted in favor of Impella over 
IABP from 2016/17 to 2019 (p=0.0489) while ECMO usage has 
remained consistent over time. This finding is supported by 
IABP-SHOCK II Trial Investigators who found that patients with 
acute MI complicated by CS did not benefit with routine IABP 
placement in addition to revascularization. 2
• Cardiogenic Shock (CS) is a high-acuity, potentially complex, and 
hemodynamically diverse state of end-organ hypoperfusion that is 
frequently associated with multisystem organ failure. Although 
survival has improved in recent years, patient morbidity and 
mortality remain high, and there are few evidence-based 
therapeutic interventions known to significantly improve patient 
outcomes.1
• The clinical presentation of CS is typically characterized by 
persistent hypotension unresponsive to volume replacement and 
is accompanied by clinical features of end-organ hypoperfusion 
requiring intervention with pharmacological or mechanical 
support, such as Intraaortic Balloon Pump (IABP), Impella, or 
Extracorporeal Membrane Oxygenation (ECMO). 1
• An analysis of the Nationwide Inpatient Sample Database between 
2003 and 2010 reported an increase in the prevalence of CS in the 
overall population and among patients >75 years of age presenting 
with STEMI. 1
